Pulmonary Perspectives®
-
Catching decompensation earlier in acute pulmonary embolism
The 2026 AHA/ACC guidelines provide a much-needed physiological road map for the modern pulmonary embolism specialist with the introduction of new classification groups.
-
Sotatercept in pulmonary arterial hypertension
Understanding when to consider sotatercept and how to use it has become a critical part of PAH care.
-
Bridging the gap: Mechanical circulatory support in lung transplantation for PAH
Review the need for ECLS, MCS, and ECMO in patients with PAH who are undergoing lung transplantation.
-
Progress and priorities in lung transplantation
Future priorities in lung transplantation will be focused on improved donor organ utilization, equitable access, and reduced impact of chronic lung allograft dysfunction.
-
Unmasking asthma disparities: The path to equitable care
Disparities in asthma care are not solely biologic but also embedded deep in the roots of our political, social, and health care systems. Clinicians have an opportunity to translate knowledge into action.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
-
A sticky road: Mucus pathology in COPD
Targeting mucus pathology could fulfill an unmet therapeutic need in managing patients with COPD and provide a novel approach to addressing the underlying mechanisms contributing to airway obstruction.
-
Navigating new ACR/CHEST guidelines for screening, monitoring, and treatment of SARD-ILD
Authors Jose R. Castellanos, MD; Anthony J. Esposito, MD; and Caroline Zhao, MD, discuss key strategies, including early screening with pulmonary function tests and high-resolution chest tomography, cautious glucocorticoid use, and personalized steroid-sparing treatment.
-
Pseudomonas infection in patients with noncystic fibrosis bronchiectasis
Pseudomonas aeruginosa is a clinically important organism that infects patients with noncystic fibrosis bronchiectasis (NCFB). In the United States, the estimated prevalence of NCFB is 213 per 100,000 across all age groups and 813 per 100,000 in the over 65 age group.1 A retrospective cohort study suggests the incidence of NCFB as ascertained from International…
-
Changing the tumor board conversation: Immunotherapy in resectable NSCLC
Without a doubt, immunotherapy has transformed the treatment landscape of non-small cell lung cancer (NSCLC) and enhanced survival rates across the different stages of disease. High recurrence rates following complete surgical resection prompted the study of immune checkpoint inhibitors (ICI) in earlier, operable stages of disease. This shift toward early application of ICI reflects the…
